CareDx, Inc. - Common Stock (CDNA)

The CEO of this leading medical diagnostic company sold shares throughout multiple days in January. But the manner in which the shares were sold shouldn't concern investors.

This transplant diagnostics specialist saw a notable insider sale amid a year of modest share price decline and ongoing product innovation.

Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.

CareDx, Inc. faces uncertainty with proposed reimbursement changes, but has long-term potential in the $8 billion transplant solutions market.

CareDx Inc (CDNA) reported mixed Q2 2025 results with revenue of $86.7M, missing estimates, but adjusted revenue rose 14% YoY. Testing volumes grew 13%, while shares fell 6.8% post-earnings.

Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps.

U.S. stock futures were lower this morning, with the Dow futures falling more than 250 points on Monday.

Ark Invest's Cathie Wood-led funds made significant trades involving GitLab, Intellia, Prime Medicine, UiPath, Ibotta, Roblox, Repare Therapeutics, and CareDx.